Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Dr. Alice Shaw on Clinical Factors Associated with Molecular Markers
Author
Howard (Jack) West, MD

I'm happy to bring you now the second part of the Santa Monica webinar, developed with the LUNGevity Foundation, on "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?", in which I was joined by Drs. Charles Rudin (Johns Hopkins University in Balimore, MD), Alice Shaw (Massachusetts General Hospital in Boston, MA), David Spigel (Sarah Cannon Cancer Center in Nashville, TN), and Glen Gloss (University of Ottawa in Ontario, Canada).  

In this short podcast, Dr. Alice Shaw reviewed the frequencies of different molecular markers in advanced NSCLC as a function of patient sex, smoking status, race, and tumor histology.  This work is very interesting, of course, because if we only do molecular marker studies of people with an adenocarcinoma or never-smokers, we not only won't ever find potentially relevant mutations in people with other histologies and those with a smoking history, but we won't have any good idea of the probabilities of finding them either.

Here is the podcast in audio and video formats, as well as the transcript and figures.

 

Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Audio Podcast

Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Transcript

Molecular Markers SM Pt 2 Shaw on Markers by Clin Factors Figs

I certainly found her presentation interesting, particularly since it highlighted some potentially fruitful targets in squamous cell carcinoma, such an underserved cancer population overdue for new treatments.

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Article
The article describes the AVO treatment, a combination therapy for Chronic Lymphocytic Leukemia (CLL), particularly for high-risk patients. CLL is a slow-growing cancer where abnormal white blood cells accumulate. "High-risk" CLL refers to cases with specific genetic changes (e.g., in TP53) that make the disease harder to treat.
Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora

Forum Discussions

I don't know what to do. No insurance

Hi Ascardino, Welcome to Grace. I'm so sorry to hear of your situation.  While we don't have specific info or expertise on ovarian cancer, I did some searching for information.  It...

Hello Janine,

Thank you for sharing this valuable leukemia playlist—building a reliable knowledge base like this truly makes a difference for everyone navigating such a challenging journey. I appreciate the open...

Recent Comments

JOIN THE CONVERSATION
New Leukemia Playlist Summer 2025
By Maxey21 on
Hi Ascardino, Welcome to…
By JanineT GRACE … on
I don't know what to do. No…
By Ascardino on
Hi Hopish hope,  Welcome to…
By JanineT GRACE … on